A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2017
At a glance
- Drugs Pneumococcal-15-valent-vaccine-conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 29 Aug 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
- 10 Mar 2016 Planned End Date changed from 1 Aug 2017 to 1 Jun 2017, according to ClinicalTrials.gov record.
- 10 Mar 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2017, according to ClinicalTrials.gov record.